Phase 3 Stroke Trial, Recruiting NCT07275749 Sponsor: Kafrelsheikh University Condition: Stroke
Back to Stroke

Phase 3 Stroke Trial, Recruiting

NCT07275749
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 80 years, either male or female, who have had their first-ever stroke affecting the back part of the brain (called a posterior-circulation stroke) and are experiencing walking or balance difficulties as a result
  • People whose stroke symptoms began no more than 24 hours before being enrolled in the trial — or, for those who woke up with stroke symptoms, within 24 hours of when they were last known to be well

Who may not be able to join:

  • People who are severely disabled from their stroke (confirm with trial site regarding the specific disability rating scale used)
  • People whose physical or mental health condition would make safe participation difficult, such as those with dementia, significantly reduced consciousness, or severe difficulty communicating
  • People who have a neurological condition that causes recurring neurological episodes, such as epilepsy, multiple sclerosis, or a brain injury that caused lasting neurological problems
  • People who received clot-dissolving medication through a vein, or who had a procedure to open blocked blood vessels in the neck, brain, or heart, within the first week of the trial
  • People who have had more than one stroke, either based on their medical history or brain scan results
  • People who have had a known allergic or sensitivity reaction to the study treatment
  • People with serious organ problems such as kidney failure or liver failure, active cancer, a known bleeding or clotting disorder, a history of bleeding in the brain, stomach or bowel bleeding within the past 6 months, or major surgery within 30 days before joining the trial
  • Women who are pregnant or breastfeeding
  • People whose stroke was caused by a blood clot in the brain's veins (cerebral venous thrombosis)
  • People whose stroke occurred in connection with a cardiac arrest

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Mohamed G. Zeinhom, MD, neurology department kafr el-sheikh university

Phone: 2001009606828

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Kafrelsheikh University
Registry
ClinicalTrials.gov
Start date
1 December 2025
Est. completion
1 July 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

value of the Berg balance scale (BBS); the rate of participants who suffered from treatment-related side effects

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov